Journal Article

DKFZ-2022-01964

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer.

Gregg, J. R. ; Kim, J. ; Logothetis, C. ; Hanash, S. ; Zhang, X. ; Manyam, G. ; Muir, K. ; Group, U. C. (Collaboration Author) ; Giles, G. G. ; Stanford, J. L. ; Berndt, S. I. ; Kogevinas, M. ; Brenner, H.DKFZ* ; Eeles, R. A. ; Consortium, P. (Collaboration Author) ; Wei, P. ; Daniel, C. R.

2023
Elsevier Amsterdam

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.euo.2022.07.008

Abstract: Coffee intake may lower prostate cancer risk and progression, but postdiagnosis outcomes by caffeine metabolism genotype are not well characterized.To evaluate associations between coffee intake, caffeine metabolism genotype, and survival in a large, multicenter study of men with prostate cancer.Data from The PRACTICAL Consortium database for 5727 men with prostate cancer from seven US, Australian, and European studies were included. The cases included had data available for the CYP1A2 -163C>A rs762551 single-nucleotide variant associated with caffeine metabolism, coffee intake, and >6 mo of follow-up.Multivariable-adjusted Cox proportional hazards models across pooled patient-level data were used to compare the effect of coffee intake (categorized as low [reference], high, or none/very low) in relation to overall survival (OS) and prostate cancer-specific survival (PCSS), with stratified analyses conducted by clinical disease risk and genotype.High coffee intake appeared to be associated with longer PCSS (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.68-1.08; p = 0.18) and OS (HR 0.90, 95% CI 0.77-1.07; p = 0.24), although results were not statistically significant. In the group with clinically localized disease, high coffee intake was associated with longer PCSS (HR 0.66, 95% CI 0.44-0.98; p = 0.040), with comparable results for the group with advanced disease (HR 0.92, 95% CI 0.69-1.23; p = 0.6). High coffee intake was associated with longer PCSS among men with the CYP1A2 AA (HR 0.67, 95% CI 0.49-0.93; p = 0.017) but not the AC/CC genotype (p = 0.8); an interaction was detected (p = 0.042). No associations with OS were observed in subgroup analyses (p > 0.05). Limitations include the nominal statistical significance and residual confounding.Coffee intake was associated with longer PCSS among men with a CYP1A2 -163AA (*1F/*1F) genotype, a finding that will require further replication.It is likely that coffee intake is associated with longer prostate cancer-specific survival in certain groups, but more research is needed to fully understand which men may benefit and why.

Keyword(s): Caffeine ; Coffee ; Genetic variation ; Mortality ; Prostatic neoplasms

Note: 2023 Jun;6(3):282-288

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie und Alternf. (C070)
2. Präventive Onkologie (C120)
3. DKTK HD zentral (HD01)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2022

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; IF >= 5 ; JCR ; SCOPUS ; Web of Science Core Collection

---